000			02340 a2200709 4500
005			20250516061528.0
264		0	_c20120213
008			201202s 0 0 eng d
022			_a1440-1746
024	7		_a10.1111/j.1440-1746.2011.06887.x _2doi
040			_aNLM _beng _cNLM
100	1		_aMiyahara, Koji
245	0	0	_aPredicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. _h[electronic resource]
260			_bJournal of gastroenterology and hepatology _cNov 2011
300			_a1604-11 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAngiogenic Proteins _xblood
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aBenzenesulfonates _xadverse effects
650	0	4	_aBiomarkers, Tumor _xblood
650	0	4	_aCarcinoma, Hepatocellular _xblood
650	0	4	_aCytokines _xblood
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aJapan
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aLiver Neoplasms _xblood
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aPredictive Value of Tests
650	0	4	_aProportional Hazards Models
650	0	4	_aProtein Kinase Inhibitors _xadverse effects
650	0	4	_aPyridines _xadverse effects
650	0	4	_aRisk Assessment
650	0	4	_aRisk Factors
650	0	4	_aSorafenib
650	0	4	_aSurvival Rate
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aUp-Regulation
700	1		_aNouso, Kazuhiro
700	1		_aTomoda, Takeshi
700	1		_aKobayashi, Sayo
700	1		_aHagihara, Hiroaki
700	1		_aKuwaki, Kenji
700	1		_aToshimori, Junichi
700	1		_aOnishi, Hideki
700	1		_aIkeda, Fusao
700	1		_aMiyake, Yasuhiro
700	1		_aNakamura, Shinichiro
700	1		_aShiraha, Hidenori
700	1		_aTakaki, Akinobu
700	1		_aYamamoto, Kazuhide
773	0		_tJournal of gastroenterology and hepatology _gvol. 26 _gno. 11 _gp. 1604-11
856	4	0	_uhttps://doi.org/10.1111/j.1440-1746.2011.06887.x _zAvailable from publisher's website
999			_c21243411 _d21243411